SB 318

Drug Profile

SB 318

Alternative Names: SB-318

Latest Information Update: 05 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sangamo Therapeutics
  • Class Gene therapies
  • Mechanism of Action Gene transference; TTK protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Mucopolysaccharidosis I
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Mucopolysaccharidosis I

Most Recent Events

  • 28 Feb 2018 Sangamo Therapeutics intends to file a Clinical Trial Authorisation application for Mucopolysaccharidosis I
  • 07 Dec 2017 The Committee for Orphan Medicinal Products issues a positive opinion on the application for orphan medicinal product designation for SB 318 for Mucopolysaccharidosis Type I
  • 13 Jul 2017 SB 318 receives Fast Track designation for Mucopolysaccharidosis I [IV,Infusion] in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top